Three-Part Viral Vector Assay for Scaled Quality Assurance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The challenge in scaling up viral vector manufacturing lies in ensuring therapeutic equivalence, safety, and purity, as existing methods struggle to consistently produce high-quality viral vectors for large-scale production.

Innovation Solution

A comprehensive assay system that measures virus infectious titer, expression of the viral transgene, and potency of the transgene expression product, utilizing flow cytometry, ELISA kits, and cytotoxicity assays to ensure quality and consistency.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If large-scale manufacturing processes are used to increase vector production capacity, then productivity is improved, but measurement precision and manufacturing precision deteriorate due to difficulty in assuring therapeutic equivalence

Engineering Contradiction:

Improvevector production capacityVSAvoidquality assurance precision

Core Design Contradiction:

ProductivityVSMeasurement precision

Solution Approach 1:

The quality assurance process is segmented into three distinct assays: infectivity assay to measure infectious titer, expression assay to measure transgene expression levels, and potency assay to measure therapeutic activity. This segmentation allows each aspect of vector quality to be independently measured and controlled, enabling precise quality assurance even at large production scales.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent establishes specific parameter ranges and acceptance criteria for each assay (infectious titer, transgene expression levels, potency measurements). By defining and controlling these parameters, the system maintains manufacturing precision across different production scales, ensuring therapeutic equivalence between small-scale and large-scale productions.

Inventive Principle:

Principle #35Parameter changes

2Manufacturing precision

If comprehensive quality assays are implemented to improve manufacturing precision, then device complexity increases

Engineering Contradiction:

Improvevector quality consistencyVSAvoidassay system complexity

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The three assays (infectivity, expression, potency) are designed to be universally applicable to different viral vector types and transgenes. Each assay uses standardized protocols and measurement approaches that can be adapted across various vector systems, reducing the need for entirely separate testing systems for different applications.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent employs homogeneous measurement approaches within each assay type, using consistent methodologies, controls, and data analysis procedures. This homogeneity simplifies the overall system by ensuring that quality assessment follows a unified framework rather than requiring disparate methods for different measurement aspects.

Inventive Principle:

Principle #33Homogeneity

3Measurement precision

If multiple assays are conducted to improve measurement precision, then loss of time increases

Engineering Contradiction:

Improvequality measurement accuracyVSAvoidassay completion time

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The assays are designed to be conducted in parallel rather than sequentially, with sample preparation and measurement procedures that can be performed simultaneously. This preliminary planning and parallel execution significantly reduces the total time required compared to sequential testing, while maintaining comprehensive quality assessment.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The assay system is designed to maintain continuous measurement and evaluation throughout the quality assurance process, with overlapping measurement phases and continuous data collection. This eliminates idle time between assays and ensures that the measurement process flows continuously, reducing overall completion time while maintaining precision.

Inventive Principle:

Principle #20Continuity of useful action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The system provides a reliable method for assessing viral vector quality, ensuring therapeutic equivalence and safety, enabling large-scale production of high-quality viral vectors.

Implementation Method 1

flow cytometry

Methodology Applied

Scientific EffectFlow cytometry:

Implementation Method 2

ELISA kits

Methodology Applied

Scientific EffectELISA:

Implementation Method 3

cytotoxicity assays

Methodology Applied

Scientific EffectCytotoxicity assay:

Data Source

PatentUS20250305000A1Viral vector assay and vector

Publication Date: 2025.10.02 FERRING VENTURES LTD

AI summary

A process for assaying viral vector manufactured by large-scale viral vector manufacturing processes to assure the resulting vector has acceptable purity and potency. The process entails three different types of assays, each one of which is optionally useful on a stand-alone basis, and which together provide the first system able to assure the quality of viral vector produced by large-scale vector manufacturing processes.